What is the official website of MSD LATAM ?

The official website of MSD LATAM is http://www.msd.com/contact/contacts.html.

What is MSD LATAM's cybersecurity risk score?

MSD LATAM has an AI-generated cybersecurity risk score of 759 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MSD LATAM experienced?

According to Rankiteo, MSD LATAM currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSD LATAM been affected by any supply chain cyber incidents ?

According to Rankiteo, MSD LATAM has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSD LATAM have SOC 2 Type 1 certification ?

According to Rankiteo, MSD LATAM is not certified under SOC 2 Type 1.

Does MSD LATAM have SOC 2 Type 2 certification ?

According to Rankiteo, MSD LATAM does not hold a SOC 2 Type 2 certification.

Does MSD LATAM comply with GDPR ?

According to Rankiteo, MSD LATAM is not listed as GDPR compliant.

Does MSD LATAM have PCI DSS certification ?

According to Rankiteo, MSD LATAM does not currently maintain PCI DSS compliance.

Does MSD LATAM comply with HIPAA ?

According to Rankiteo, MSD LATAM is not compliant with HIPAA regulations.

Does MSD LATAM have ISO 27001 certification ?

According to Rankiteo,MSD LATAM is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSD LATAM operate in ?

MSD LATAM operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSD LATAM have ?

MSD LATAM employs approximately 585 people worldwide.

Does MSD LATAM own any subsidiaries ?

MSD LATAM presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSD LATAM have ?

MSD LATAM's official LinkedIn profile has approximately 132,300 followers.

Does MSD LATAM have a Crunchbase profile ?

No, MSD LATAM does not have a profile on Crunchbase.

Does MSD LATAM have a LinkedIn profile ?

Yes, MSD LATAM maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msd-latam.

How many cybersecurity incidents has MSD LATAM experienced ?

As of August 3, 2026, Rankiteo reports that MSD LATAM has experienced 1 cybersecurity incidents.

How many peer or competitor companies does MSD LATAM have ?

MSD LATAM has an estimated 5,720 peer or competitor companies worldwide.

What types of cybersecurity incidents has MSD LATAM faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSD LATAM

Boost Score +25 with badge (5 left)

759

/1000

Fair

784

/1000

Fair

MSD LATAM Vendor Cyber Rating & Cyber Score

msd.com

Add Your Compliance Badge

En MSD, conocida como Merck & Co., Inc., Rahway, NJ, EE. UU. en los Estados Unidos y Canadá, nos unimos en torno a nuestro propósito: utilizamos el poder de la ciencia de vanguardia para salvar y mejorar vidas en todo el mundo. Durante más de 130 años, hemos brindado esperanza a la humanidad a través del desarrollo de importantes medicamentos y vacunas. Aspiramos a ser la principal empresa biofarmacéutica de investigación intensiva del mundo, y hoy estamos a la vanguardia de la investigación para ofrecer soluciones de salud innovadoras que promuevan la prevención y el tratamiento de enfermedades en personas y animales. Fomentamos una fuerza laboral global diversa e inclusiva y operamos de manera responsable todos los días para permitir un

MSD LATAM A.I CyberSecurity Scoring

Scoring History

MSD LATAM

MSD LATAM CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

MSD LATAM

Breach

9/2025

MSD060270611182...

Loading…

A.I.

MSD LATAM Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSD LATAM

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD LATAM in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSD LATAM in 2026.

Incident Types MSD LATAM vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD LATAM in 2026.

Incident History - MSD LATAM (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSD LATAM Subsidiaries

MSD LATAM

Pharmaceutical Manufacturing

Website: http://www.msd.com/contact/contacts.html

Company Size: 585

MSDPharmaceutical Manufacturing

MSD Saúde AnimalVeterinary Services

MSD Animal HealthPharmaceutical Manufacturing

MSD EspañaPharmaceutical Manufacturing

MSD EgyptPharmaceutical Manufacturing

MSD FrancePharmaceutical Manufacturing

MSD NetherlandsPharmaceutical Manufacturing

MSD DeutschlandPharmaceutical Manufacturing

MSD TürkiyePharmaceutical Manufacturing

MSD GCCPharmaceutical Manufacturing

MSD PortugalPharmaceutical Manufacturing

MSD SwitzerlandPharmaceutical Manufacturing

MSD ItaliaPharmaceutical Manufacturing

MSD in the UKPharmaceutical Manufacturing

MSD Australia & New ZealandPharmaceutical Manufacturing

MSD GreecePharmaceutical Manufacturing

MSD South AfricaPharmaceutical Manufacturing

MSD Animal Health Technology LabsTechnology, Information and Internet

MSD BelgiumPharmaceutical Manufacturing

MSD PolskaPharmaceutical Manufacturing

MSD Czech RepublicPharmaceutical Manufacturing

MSD JordanPharmaceutical Manufacturing

MSD RomaniaPharmaceutical Manufacturing

MSD Animal Health UK LtdPharmaceutical Manufacturing

MSD SverigePharmaceutical Manufacturing

MSD LebanonPharmaceutical Manufacturing

MSD FinlandPharmaceutical Manufacturing

MSD DanmarkPharmaceutical Manufacturing

MSD NorgePharmaceutical Manufacturing

MSD SlovenskoPharmaceutical Manufacturing

MSD SRBIJAPharmaceutical Manufacturing

MSD ÖsterreichPharmaceutical Manufacturing

MSD UkrainePharmaceutical Manufacturing

MSD MagyarországPharmaceutical Manufacturing

Loading…

MSD LATAM Similar Companies

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Loading…

NEWS

MSD LATAM CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-18577

SUMMARY

An incomplete patch for CVE-2026-18556 allows for authentication bypass and account takeover in N-central Versions through 2026.3.1

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:L/SI:L/SA:L/E:A/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-10848

SUMMARY

The OCPP 1.6 client in subsys/net/lib/ocpp parsed inbound WAMP RPC frames in parse_rpc_msg() (subsys/net/lib/ocpp/ocpp_j.c) using a hand-rolled helper, extract_string_field(), that copied the message's uid and action fields with strncpy(out_buf, token + 1, outlen - 1) and then scanned the result with strchr(out_buf, '"'). Because strncpy does not NUL-terminate the destination when the source is at least outlen - 1 (127) bytes long, the subsequent strchr reads past the 128-byte destination buffer into adjacent stack memory; if a " byte is found beyond the buffer, a one-byte out-of-bounds NUL write also occurs. A related defect in extract_payload() runs strchr/strrchr over the receive buffer, which may not be NUL-terminated when a maximal-length frame fills it. The parsed bytes come directly from the OCPP central-system server over a websocket: the reader thread fills recv_buf via websocket_recv_msg() and calls parse_rpc_msg() on each inbound DATA frame (subsys/net/lib/ocpp/ocpp.c). A malicious or compromised central server, or an on-path attacker (OCPP is commonly deployed over plain ws://), can send an RPC frame whose uid or action field is 127+ bytes with no closing quote, triggering the out-of-bounds access. The primary impact is a remotely triggerable denial of service: the unbounded scan can fault on an unmapped page, and the stray NUL write can corrupt adjacent stack state. The over-read data is not reflected to the peer, so disclosure is limited. The feature is EXPERIMENTAL and must be explicitly enabled (CONFIG_OCPP). The fix replaces the manual parser with the bounds-respecting json_mixed_arr_parse() and copies the extracted uid with an explicitly NUL-terminated buffer, eliminating both over-reads.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 7)

cvss3

Base Score: 7.0

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:L/A:H

Impact Score

4.7

Exploitability

2.2

REFERENCES

CVE-2026-9856

SUMMARY

A vulnerability in huggingface/transformers versions <=5.8.0.dev0 allows an attacker to perform arbitrary file writes via path traversal. The issue resides in the `save_pretrained()` methods of `PreTrainedTokenizerBase` and `ProcessorMixin`, where keys from the `chat_template` dictionary are used directly as filenames without proper validation. An attacker can exploit this by publishing a malicious Hugging Face Hub repository with a crafted `tokenizer_config.json` file. When a victim downloads and saves the tokenizer or processor, the attacker-controlled keys can escape the intended save directory, enabling arbitrary file writes with attacker-controlled content. This vulnerability affects multiple processors inheriting from `ProcessorMixin`, including Idefics, Florence, Gemma, Phi, and Qwen-VL.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.0/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:H/A:L

Impact Score

4.2

Exploitability

2.8

REFERENCES

CVE-2026-65321

SUMMARY

PyAthena prior to 3.35.4 contains a sql injection vulnerability that allows unauthenticated attackers to inject arbitrary SQL by exploiting improper quote-escaping in DefaultParameterFormatter.format(), which routes DELETE and CTAS statements to the _escape_hive function that backslash-escapes single quotes rather than doubling them. Because Athena and Trino do not treat backslashes as escape characters inside string literals, attacker-supplied input such as a single quote followed by SQL syntax causes the parser to terminate the string literal prematurely, enabling data exfiltration via UNION SELECT, execution of destructive statements, and attacker-controlled CTAS destination and content.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-10774

SUMMARY

Zephyr's Bluetooth Mesh subnet key management leaks one PSA Crypto key slot on every subnet-key teardown. In subsys/bluetooth/mesh/subnet.c, net_keys_create() imports the Private Beacon Key into a PSA key slot under CONFIG_BT_MESH_PRIV_BEACONS (enabled by default), but subnet_keys_destroy() guarded the matching psa_destroy_key() with CONFIG_BT_MESH_V1d1. That Kconfig symbol was removed when explicit Mesh 1.0.1 support was dropped, so the destroy branch became permanently dead code and the import is never balanced by a destroy. The imbalanced teardown is reached every time subnet keys are destroyed: deleting a subnet (Config Server NetKey Delete), completing a Key Refresh Procedure (which retires the old key set), and resetting/re-provisioning the node. The over-the-air triggers are processed only under the node's device key, so they are exercisable by the provisioner or network administrator that owns the node, reachable over the Bluetooth Mesh network. With the default CONFIG_MBEDTLS_PSA_KEY_SLOT_COUNT of 16, repeated add/delete or key-refresh cycles exhaust the shared PSA key-slot pool after roughly a dozen rounds. Once exhausted, bt_mesh_private_beacon_key() and thus subnet creation fail: the node can no longer add subnets or complete key refresh, and other PSA crypto consumers on the device may be starved, until the device is rebooted. The fix aligns the destroy guard with the import guard (CONFIG_BT_MESH_PRIV_BEACONS) so each slot is freed.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 2.4)

cvss3

Base Score: 2.4

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:H/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

0.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…